Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Aug;42(2):305–313. doi: 10.1038/bjc.1980.231

Plasminogen activator in cultured Lewis lung carcinoma cells measured by chromogenic substrate assay.

P Whur, M Magudia, J Boston, J Lockwood, D C Williams
PMCID: PMC2010387  PMID: 7191713

Abstract

A chromogenic substrate assay for the plasminogen activator (PA) activity of Lewis lung carcinoma cells has been developed. The cells were incubated with plasminogen, the activation of which to plasmin was measured by the amidolysis of the chromogenic substrate S-2251. This was routinely performed as a 4h serum-free assay, but a variation lasting 24 h, in medium supplemented with plasminogen-free inhibitor-reduced serum, produced similar results. The assay also detected PA released into the medium. PA activity was proportional to cell density, and the assay was non-toxic to the cells. Assays were performed on cultures derived from primary and metastatic tumours. Host cells were effectively eliminated from such cultures but, because of an initial phase of tumour-cell death, PA assays were not carried out until cultures became established. No consistent difference was detected between PA levels in primary and metastatic cultures. However, these cultures were shown to be atypical of the parent tumour; they grew slowly when reinjected at the primary site, and their metastatic potential was impaired.

Full text

PDF
305

Images in this article

310Fig. 7
on p.310

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Claeson G., Aurell L., Friberger P., Gustavsson S., Karlsson G. Designing of peptide substrates. Different approaches exemplified by new chromogenic substrates for kallikreins and urokinase. Haemostasis. 1978;7(2-3):62–68. doi: 10.1159/000214236. [DOI] [PubMed] [Google Scholar]
  2. Fidler I. J., Gersten D. M., Kripke M. L. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res. 1979 Oct;39(10):3816–3821. [PubMed] [Google Scholar]
  3. Fidler I. J. Selection of successive tumour lines for metastasis. Nat New Biol. 1973 Apr 4;242(118):148–149. doi: 10.1038/newbio242148a0. [DOI] [PubMed] [Google Scholar]
  4. Goldberg A. R. Increased protease levels in transformed cells: a casein overlay assay for the detection of plasminogen activator production. Cell. 1974 Jun;2(2):95–102. doi: 10.1016/0092-8674(74)90097-x. [DOI] [PubMed] [Google Scholar]
  5. Guy D., Latner A. L., Turner G. A. Surface protein distributions in cells isolated from solid tumours and their metastases. Br J Cancer. 1979 Oct;40(4):634–640. doi: 10.1038/bjc.1979.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones P., Benedict W., Strickland S., Reich E. Fibrin overlay methods for the detection of single transformed cells and colonies of transformed cells. Cell. 1975 Jul;5(3):323–329. doi: 10.1016/0092-8674(75)90108-7. [DOI] [PubMed] [Google Scholar]
  7. Kohga S. Thromboplastic and fibrinolytic activities of ascites tumor cells of rats, with reference to their role in metastasis formation. Gan. 1978 Aug;69(4):461–470. [PubMed] [Google Scholar]
  8. Marsh N. A., Gaffney P. J. The rapid fibrin plate - a method for plasminogen activator assay. Thromb Haemost. 1977 Aug 31;38(2):545–551. [PubMed] [Google Scholar]
  9. Ossowski L., Quigley J. P., Kellerman G. M., Reich E. Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J Exp Med. 1973 Nov 1;138(5):1056–1064. doi: 10.1084/jem.138.5.1056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Peterson H. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumours. Cancer Treat Rev. 1977 Sep;4(3):213–217. doi: 10.1016/s0305-7372(77)80025-x. [DOI] [PubMed] [Google Scholar]
  11. Sherman M. I., Strickland S., Reich E. Differentiation of early mouse embryonic and teratocarcinoma cells in vitro: plasminogen activator production. Cancer Res. 1976 Nov;36(11 Pt 2):4208–4216. [PubMed] [Google Scholar]
  12. Stephens T. C., Peacock J. H., Steel G. G. Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation. Br J Cancer. 1977 Jul;36(1):84–93. doi: 10.1038/bjc.1977.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. TODD A. S. The histological localisation of fibrinolysin activator. J Pathol Bacteriol. 1959 Jul;78:281–283. doi: 10.1002/path.1700780131. [DOI] [PubMed] [Google Scholar]
  14. Unkeless J. C., Gordon S., Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med. 1974 Apr 1;139(4):834–850. doi: 10.1084/jem.139.4.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Whur P., Silcox J. J., Boston J. A., Williams D. C. Plasminogen activation transforms the morphology of quiescent 3T3 cell monolayers and initiates growth. Br J Cancer. 1979 Jun;39(6):718–730. doi: 10.1038/bjc.1979.126. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES